Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

EXELON 2 MG

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 2 MG · DIN 02245240 · KNIGHT THERAPEUTICS INC.

Health Canada status: MARKETED

What is EXELON?

EXELON 2 MG contains RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02245240, held by KNIGHT THERAPEUTICS INC., supplied as SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Nov-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is EXELON used for?

EXELON® (rivastigmine hydrogen tartrate) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. EXELON® is indicated for the symptomatic treatment of patients with idiopathic Parkinson’s disease, and mild to moderate dementia, with onset at least 2 years after the initial diagnosis of Parkinson’s disease, and in whom other causes of dementia have been ruled out.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

What else is EXELON called?

The same molecule, RIVASTIGMINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
NIMVASTIDLatinCzechia
ZeyzelfLatinSaudi Arabia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02245240
Brand nameEXELON
Generic / active ingredientRIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 2 MG
ManufacturerKNIGHT THERAPEUTICS INC.
Strength2 MG
Dosage formSOLUTION
Route of administrationORAL
SchedulePrescription
ATC codeN06DA03 RIVASTIGMINE
AHFS class12:04.00
BiosimilarNo
Health Canada statusMARKETED
Status date18-Nov-2022
Original market date2002-12-05 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02245240
DIN (unpadded, as printed on some documents)2245240
Brand nameEXELON
Active ingredient / INNRIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) : 2 MG
ATC codeN06DA03
ATC anatomical main groupN — Nervous system
ATC therapeutic subgroupN06
AHFS class12:04.00
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderKNIGHT THERAPEUTICS INC.

Health Canada approved product monograph (PDF)

How is it stored and handled?

null

How is it supplied?

Capsules: Cartons containing 4 blister strips of 14 capsules. Oral solution: 120 mL amber glass bottles.

Which pack is which?

Strength on the label2 MG
Dosage formSOLUTION
RouteORAL
Packaging as described in the monographCapsules: Cartons containing 4 blister strips of 14 capsules. Oral solution: 120 mL amber glass bottles.
Storagenull

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Confirm the pack and get a price

What can be used instead?

Other Canadian products sharing ATC code N06DA03 RIVASTIGMINE. 28 of 80 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
APO-RIVASTIGMINE1.5 MGCAPSULEAPOTEX INCMARKETEDDIN 02336715
APO-RIVASTIGMINE3 MGCAPSULEAPOTEX INCMARKETEDDIN 02336723
APO-RIVASTIGMINE4.5 MGCAPSULEAPOTEX INCMARKETEDDIN 02336731
APO-RIVASTIGMINE6 MGCAPSULEAPOTEX INCMARKETEDDIN 02336758
EXELON1.5 MGCAPSULEKNIGHT THERAPEUTICS INC.MARKETEDDIN 02242115
EXELON3 MGCAPSULEKNIGHT THERAPEUTICS INC.MARKETEDDIN 02242116
EXELON4.5 MGCAPSULEKNIGHT THERAPEUTICS INC.MARKETEDDIN 02242117
EXELON6 MGCAPSULEKNIGHT THERAPEUTICS INC.MARKETEDDIN 02242118
EXELON PATCH 109.5 MG / 24 HOURPATCHKNIGHT THERAPEUTICS INC.MARKETEDDIN 02302853
EXELON PATCH 1513.3 MG / 24 HOURPATCHKNIGHT THERAPEUTICS INC.MARKETEDDIN 02432803

Who else supplies RIVASTIGMINE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. RIVASTIGMINE appears in 242 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does RIVASTIGMINE cost around the world?

RIVASTIGMINE is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
United Statesacquisition766USD███.██
AustriaKVP (Kassenverkaufspreis)3343EUR███.██
Greeceproducer price (ex-factory)2222EUR███.██
Saudi Arabiapublic1719SAR███.██
Australiaex-manufacturer414AUD███.██
Czechiamax producer price (ex-factory)214CZK███.██
United Kingdomhospital88GBP███.██
Luxembourgreimbursement88EUR███.██
South Africasingle exit price78ZAR███.██
Hungaryproducer price (ex-factory)57HUF███.██
Bahrainretail (max)12BHD███.██
MoroccoPPV (public price)22MAD███.██

213 pack listings across 116 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every RIVASTIGMINE pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for EXELON

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02245240. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.